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Aims Video-assisted thoracoscopic surgery (VATS) ablation has been advocated as a treatment option for non-
paroxysmal atrial fibrillation (AF) in recent guidelines. Real-life data on its safety and efficacy during a centre’s early
experience are sparse.
...................................................................................................................................................................................................
Methods
and results
Thirty patients (28 persistent/longstanding persistent AF) underwent standalone VATS ablation for AF by an expe-
rienced thoracoscopic surgeon, with the first 20 cases proctored by external surgeons. Procedural and follow-up
outcomes were collected prospectively, and compared with 90 propensity-matched patients undergoing contem-
poraneous catheter ablation (CA). Six (20.0%) patients undergoing VATS ablation experienced >_1 major complica-
tion (death n= 1, stroke n= 2, conversion to sternotomy n= 3, and phrenic nerve injury n= 2). This was signifi-
cantly higher than the 1.1% major complication rate (tamponade requiring drainage n= 1) seen with CA
(P< 0.001). Twelve-month single procedure arrhythmia-free survival rates without antiarrhythmic drugs were 56%
in the VATS and 57% in the CA cohorts (P= 0.22), and 78% and 80%, respectively given an additional CA and anti-
arrhythmic drugs (P= 0.32).
...................................................................................................................................................................................................
Conclusion During a centre’s early experience, VATS ablation may have similar success rates to those from an established CA
service, but carry a greater risk of major complications. Those embarking on a programme of VATS AF ablation
should be aware that complication and success rates may differ from those reported by selected high-volume centres.
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Introduction
Minimally invasive surgical ablation of atrial fibrillation (AF) using
video-assisted thoracoscopic surgery (VATS) is growing in popularity.
Recent guidelines advocate VATS AF ablation as a viable treatment
option,1,2 with some placing it on a par with catheter ablation (CA)
for patients with non-paroxysmal AF.1 However, a recent meta-
analysis3 showed the reported outcomes from VATS AF ablation are
highly variable, with success rates ranging from 40%4 to 96%5 at
12 months. Furthermore, this meta-analysis showed that the defini-
tion of complications varies widely between studies. While case se-
ries report major complication rates as low as 0% e.g. Ref.6
prospectively collected data from randomized studies suggests
complication rates may be up to 23%.7 In view of this, concerns have
been raised over possible under-reporting of complications, and
the latest AF guidelines have highlighted VATS ablation as one of
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the ‘Gaps in Evidence’ for which further research needs to be
prioritized.2
We present our initial experience of VATS ablation for AF, and
compare procedural and clinical outcomes with a propensity-
matched cohort of patients treated by our well-established CA
service. We present our success rates according to consensus guide-
lines8 and report our complication rates in full, thereby providing an
accurate reflection of what can be expected when starting a
programme of VATS ablation.
Methods
Patients
Liverpool Heart and Chest Hospital is one of the largest cardiothoracic
centres in England with an established high-volume CA programme for
AF, survival rates from thoracic surgery significantly better than the na-
tional average (www.scts.org), and an ‘Outstanding’ rating from the Care
Quality Commission. From late 2013, and as per the National Institute for
Health and Care Excellence (NICE) AF guidance,1 patients with non-
paroxysmal AF referred for CA to our centres were offered the choice of
undergoing VATS AF ablation instead. Patients were excluded if they had a
co-existing indication for cardiac surgery such as severe valvular heart dis-
ease. Severe atrial dilatation was not an exclusion criterion. In order to
avoid dilution of surgical experience, VATS AF ablation was restricted to a
single thoracic surgeon (N.M.) already experienced in VATS techniques.
We mandated external proctoring for the first 20 VATS cases by surgeons
with extensive experience of VATS AF ablation from other centres.
From December 2013 to May 2017, 35 consecutive patients under-
went standalone VATS ablation for AF. Of the first 20 cases, while the
first two were performed in December 2013, a hiatus ensued because of
funding limitations before the programme recommenced in January 2015.
The remaining 18 cases were performed between January 2015 and
December 2015. During the same time period, 1032 patients underwent
radiofrequency CA for AF. For the purpose of this report, five VATS
patients and 105 CA patients were excluded as they had been recruited
into research trials reported elsewhere. Propensity matching amongst
the remaining CA cohort in a 3:1 ratio identified 90 patients whose out-
comes were compared with the 30 VATS patients. An institutional re-
view board-approved electronic patient record was used for prospective
data capture for all patients, and the data were collated retrospectively
for the catheter cohort after propensity matching had identified the
group. Each patient gave written consent for their procedure, and to their
data being included in this study.
Surgical ablation technique
Procedures were performed thoracoscopically under general anaesthesia
with sequential single lung ventilation using either a double-lumen tube or
bronchial blocker. Patients were positioned supine, with slight reverse
Trendelenburg tilt.
The right side was operated on first using three ports in the anterior
axillary line after isolation of the ipsilateral lung and carbon dioxide insuf-
flation. The pericardium was opened longitudinally 2 cm anterior and par-
allel to the phrenic nerve. The inferior edge of the pericardium was
retracted with three sutures using the Endo Stitch (Covidien). Dissection
between the atrium and pericardium allowed access to the oblique sinus
adjacent to the right inferior pulmonary vein (PV). Further dissection
along the right superior PV towards the left superior PV exposed the
roof of the left atrium. The illuminated Lumitip (AtriCure) dissector facili-
tated passing the jaws of the bipolar radiofrequency clamp around the
right PVs. At least six overlapping ablation lines were created at the an-
trum of the right PVs. The Isolator Multifunction Pen (AtriCure) was
used to create linear ablation lines along the transverse sinus from the
right superior PV to the left, with a similar ablation line connecting the
right and left inferior PVs. Ganglionic plexi, with specific targeting of the
inferior plexi around the coronary sinus, were identified by eliciting a va-
gal response to rapid stimulation, and ablated until this response was
eliminated.
On the left, three ports were positioned in the midaxillary line. The
pericardium was opened posterior and parallel to the phrenic nerve.
After division of the ligament of Marshall, the tissue between the left su-
perior PV and left pulmonary artery was dissected towards the oblique si-
nus. The left PVs were isolated with the aid of the Lumitip with at least six
overlapping ablation lines. The connecting lines were completed from the
left towards the right using the multifunction pen. Electrical block was
confirmed by absence of PV signals and on the posterior wall using the
pen to sense. Finally the AtriClip (AtriCure) was deployed extrinsically at
the base of the left atrial appendage (LAA) under transoesophageal echo-
cardiographic guidance.
Catheter ablation technique
Our CA technique has been described previously.9 Procedures were per-
formed under general anaesthesia or conscious sedation. Patients taking
warfarin continued uninterrupted anticoagulation, while patients taking
non-vitamin K oral anticoagulants had 0–2 doses omitted at the opera-
tor’s discretion. Patients who had not maintained therapeutic anticoagula-
tion for 4 weeks pre-procedure underwent transoesophageal
echocardiography. Ultrasound-guided vascular access was obtained via
the right femoral vein.10 Two trans-septal punctures were performed and
unfractionated heparin was used to maintain an activated clotting time of
>250 s. A 3.5 mm contact force-sensing irrigated tip ablation catheter
(SmarttouchTM) was used with the CARTO mapping system (Biosense
Webster, Irvine, CA, USA) aiming for contact force of 5–40 g for each le-
sion. Since December 2014, minimum ablation index values of 550 on the
anterior wall and 400 on the posterior wall were targeted.9 Pulmonary
vein isolation (PVI) was mandatory for all patients while additional abla-
tion was performed at operator’s discretion. Successful PVI was defined
as entrance block confirmed with a 20-pole spiral catheter, and successful
linear lesions were defined as bidirectional block. Details of the CA pro-
cedure were prospectively captured in a bespoke electronic AF ablation
database.
Definitions
Classification of AF, and procedural success were defined according to
ACC/AHA/HRS guidelines,8 being survival free from any atrial arrhyth-
mias >30 s after a 3-month blanking period. Success was defined on an
What’s new?
• Previous studies have suggested that thoracoscopic ablation
for atrial fibrillation is more effective than catheter ablation
(CA), but at the cost of a higher complication rate.
• These earlier studies were largely performed using older CA
technology, and therefore, may underestimate the efficacy
seen if more modern techniques had been used.
• During the institutional learning curve for thoracoscopic abla-
tion, surgical ablation was associated with similar success rates
to CA performed using modern technology, but still carried a
significantly higher complication rate.
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intention-to-treat basis including those deceased. All complications that
caused prolonged morbidity, increased the duration of planned hospital
stay, or prompted readmission were reported and classified according to
the Ottawa Thoracic Morbidity and Mortality classification system.11
Follow-up
Patients were followed up at 3 months, 6 months, and 12 months post-
procedure with additional clinic visits as required. A 12-lead ECG was
recorded at each visit. Additional ambulatory ECG monitoring was per-
formed at physician’s discretion depending upon the temporal pattern of
symptoms. Records of hospital attendances at referring hospitals were
also inspected for evidence of complications or arrhythmia recurrence.
Statistical analysis
Pre-operative variables were used to develop a propensity score match-
ing patients who had undergone CA to those having undergone VATS ab-
lation using a 3:1 digit greedy matching algorithm based on age, sex,
classification of AF, and left atrial diameter.12 If a match could not be
found using a full propensity score, the algorithm then proceeded to the
next highest digit of the propensity score (from a seven-digit down to
one-digit match) to determine next-best matches. This was performed in
a hierarchical sequence until no more matches could be found. Matching
was performed without replacement.
Continuous data are presented as mean ± standard deviation or me-
dian (range) for normally and non-normally distributed data, respectively.
The Wilcoxon rank sum and v2 tests were used for univariable compari-
sons. McNemar and signed rank tests were used as appropriate for
matched pairs. The Log-rank test was used to compare survival curves.
Statistical analyses were performed using SAS for Windows (Version 9.3,
SAS, Cary, NC, USA) and SigmaPlot (Systat Software, CA, USA).
Statistical significance was taken as P< 0.05.
Results
Propensity matching on age, sex, AF classification, and left atrial diam-
eter yielded groups that were similar with regard to all measured
pre-procedural demographics (Table 1). The majority of patients
(92%) had persistent or longstanding-persistent AF. The two patients
undergoing VATS ablation who had paroxysmal AF had undergone
unsuccessful attempts at CA, one having undergone percutaneous
closure of an atrial septal defect making trans-septal puncture
impossible.
Procedural details and lesions sets can be found in Figure 1 and
Table 2. One surgical case was terminated prior to any ablation being
performed due to extensive pericardial adhesions; there were no
clinical risk factors or features on his pre-procedural CT suggesting
adhesions. This patient underwent CA at 4 months and remained
free from recurrent atrial arrhythmias until last follow-up at
20 months. The case has been included in the analysis of peri-
procedural outcomes but excluded from the analyses of follow-up
and freedom from arrhythmia. No CA cases required termination
before the PVs had been isolated. The most common reasons for fail-
ure to complete the intended surgical lesion set were unfavourable
anatomy or procedure termination due to a complication.
At discharge, similar proportions of warfarin vs. non-vitamin K
antagonists were used in each group (surgical: warfarin n= 17, rivar-
oxaban n= 6, and apixaban n= 5; catheter: warfarin n= 47, rivaroxa-
ban n= 15, apixaban n= 20, and dabigatran n= 8).
Follow-up
Duration of follow-up and number of outpatient attendances were
similar between groups (surgical 17.7 ± 7.4 months, 4.4± 2.0 attend-
ances; catheter 17.9± 9.8 months, 3.8 ± 2.6 attendances, P= 0.92,
P= 0.25, respectively). Ambulatory monitoring was performed more
frequently in the VATS cohort [surgical 23/28 (82%) and catheter 27/
90 (30%), P< 0.01]. Similar proportions of patients were anticoagu-
lated at last follow-up [surgical 20/29 (69%) and catheter 95/120
(79%), P= 0.24].
Post-discharge DC cardioversion was performed in more patients
from the VATS cohort [surgical 13/28 (46.4%), of which 6/28 (21.4%)
in the post-blanking period; catheter 16/90 (17.8%), of which 4/90
(4.4%) in the post-blanking period; P= 0.02, P< 0.01]. Additional CA
was performed in 5/28 (17.9%) surgical (involving left atrium n= 4)
and 16/90 (17.8%) catheter patients (involving left atrium n= 16),
P= 0.99. Repeat electrophysiological studies showed similar numbers
of PV reconnections between groups (surgical 1.0, catheter 1.7,
P= 0.25). Reconnection of the posterior wall was seen in two out of
four surgical patients and three out of five catheter patients in whom
this lesion set had been performed.
Complications
Complications are summarized in Table 3. Six out of 30 (20.0%)
patients undergoing VATS ablation experienced one or more major
(Ottawa Grade IIIþ) complications. One patient with highly symp-
tomatic persistent AF who suffered from hypertrophic cardiomyopa-
thy and pulmonary fibrosis suffered respiratory failure on post-
operative Day 6, a stroke on Day 11, and died on Day 12. Following
this case, we no longer offer VATS ablation to patients with pulmo-
nary fibrosis.
.................................................................................................
Table 1 Demographics
Surgical
(n530)
Catheter
(n5 90)
P-value
Age (years) 58 ± 9.9 57.9 ± 9.8 0.95
Male (%) 86.7% 80.0% 0.41
BMI (kgm2) 31.7 ± 4.3 30.5 ± 44 0.19
eGFR 66.7 ± 12.8 68.7 ± 17.1 0.60
CHA2DS2VASc 1.1 ± 0.9 15 ± 1.3 0.18
EuroSCORE II 0.9% ± 0.3% 0.8% ± 0.3% 0.61
PAF (%) 6.7% 8.9% 0.92
PerAF (%) 50.0% 47.8% 0.92
LSperAF (%) 43.3% 43.3% 0.92
AF duration (years) 4.3 ± 3.7 4.5 ± 5.3 0.82
DCCV (%) 83.3% 67.8% 0.10
Previous catheter
ablation (%)
6.7% 6.7% 1.00
LV ejection fraction (%) 52.3% ± 6.5% 49.6% ± 8.3% 0.11
LA diameter (mm) 46.1 ± 5 46.1 ± 5.2 0.96
LA volume (mL) 90.8 ± 18.4 98.1 ± 32.6 0.46
AF, atrial fibrillation; BMI, body mass index; DCCV, prior direct current cardio-
version; eGFR, estimated glomerular filtration rate; LA, left atrial; LSperAF, long-
standing persistent atrial fibrillation; LV, left ventricle; PAF, paroxysmal atrial
fibrillation; PerAF, persistent atrial fibrillation.
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Three patients experienced cardiac perforations. One patient suf-
fered a perforation at the base of the LAA before the clip had been
applied and suffered a stroke on Day 0 leaving him with a homony-
mous hemianopia. A second patient suffered a perforation of the pos-
terior left atrium during passage of the Lumitip dissector. A third
patient suffered a perforation of the right inferior PV during passage
of the Lumitip dissector. In each case, the perforation was repaired
via midline sternotomy.
One patient suffered a left phrenic nerve transection while dissect-
ing fat from the left hilum. This was re-apposed immediately via tho-
racotomy. Phrenic nerve function recovered by 6 months. A second
patient experienced a right phrenic nerve injury which was identified
during readmission for thoracotomy to drain an empyema. The
mechanism of this injury is uncertain. Two patients experienced pleu-
ral effusions requiring readmission to hospital for percutaneous
drainage. A further two patients suffered chest infections causing re-
spiratory failure that required CPAP, and one patient required hospi-
tal readmission for a wound infection.
One out of 90 (1.1%) patients undergoing CA experienced a major
complication. This patient suffered a pericardial effusion requiring
percutaneous drainage. Another patient was found to have a pericar-
dial effusion without tamponade that was managed conservatively.
Figure 1 Posterior view of left atrium showing (A) surgical ablation lesion set and (B) catheter ablation lesion set. LAA, left atrial appendage; LIPV,
left inferior pulmonary vein; LSPV, left superior pulmonary vein; RIPV, right inferior pulmonary vein; RSPV, right superior pulmonary vein; SVC, supe-
rior vena cava.
.................................................................................................
Table 2 Procedural characteristics
Surgical
(n5 30)
Catheter
(n5 90)
P-value
PVI 29 (96.7%) 90 (100%) 0.56
Roof line 26 (86.7%) 37 (41.1%) <0.01
Floor line 26 (86.7%) 23 (25.6%) <0.01
Ganglionic plexi 26 (86.7%) 0 (0%) <0.01
LAA exclusion 24 (80%) 0 (0%) <0.01
CTI line 0 (0%) 18 (20%) 0.02
MIG line 0 (0%) 5 (5.6%) 0.43
Procedure duration (min) 248 ± 63 176 ± 38 <0.01
Length of hospital stay (days) 7 ± 3 2 ± 0.2 <0.01
CTI, cavo-tricuspid isthmus; LAA, left atrial appendage; MIG, mitral isthmus
gauche; PVI, pulmonary vein isolation.
Bold text indicates P<0.05.
.................................................................................................
Table 3 Incidence of complications (non-hierarchical)
graded by Ottawa thoracic morbidity and mortality
classification
Complications Surgical
(n5 30),
n (%)
Catheter
(n5 90),
n (%)
Major
Grade V
Death 1 (3.3) 0 (0.0)
Grade IV
Stroke 2 (6.7) 0 (0.0)
Grade III
Atrial tear requiring sternotomy 3 (10) 0 (0.0)
Phrenic nerve injury 2 (6.7) 0 (0.0)
Need for pacemaker 0 (0) 0 (0.0)
Pericardial effusion requiring drainage 0 (0) 1 (1.1)
Minor
Grade II
Pleural effusion 4 (13.3) 0 (0.0)
Pneumothorax 0 (0) 0 (0.0)
Pericardial effusion without drainage 0 (0) 1 (1.1)
Respiratory failure requiring CPAP 3 (10) 0 (0.0)
Infection requiring antibiotics 5 (10) 1 (1.1)
Bleeding requiring transfusion 3 (10) 0 (0.0)
Pericarditis 0 (0.0) 2 (2.2)
Oesophageal dysmotility 0 (0.0) 1 (1.1)
Adverse events unrelated to procedure
Post-discharge mortality 0 (0.0) 1 (1.1)
CPAP, continuous positive airway pressure ventilation.
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Two patients sought medical attention for pericarditis, and one expe-
rienced symptoms attributed to oesophageal dysmotility caused by
the procedure. No CA patients experienced vascular complications
requiring intervention. One patient in the CA group with a pre-
existing ischaemic cardiomyopathy suffered a fatal myocardial infarc-
tion during follow-up which was not attributable to the procedure.
Arrhythmia-free survival
Thirteen out of 28 surgical and 32/120 catheter patients experienced
recurrent atrial arrhythmias during follow-up. Every patient in whom
recurrent arrhythmias were detected on ambulatory monitoring also
had evidence of recurrence on a standard 12-lead ECG. Arrhythmia
recurrence was more likely to be due to atrial tachycardia or flutter
in the VATS cohort [surgical 5/13 (38.5%) and catheter 2/32 (6.2%),
P< 0.01]. At last follow-up, survival free from any atrial arrhythmias
after a single procedure was similar between groups [surgical 15/29
(51.7%) and catheter 53/90 (58.9%), P= 0.22 by log rank, Figure 2A].
Arrhythmia-free survival was also similar allowing for an additional
CA [surgical 18/29 (62.1%) and catheter 62/90 (68.9%), P= 0.32 by
log rank, Figure 2B]. At last follow-up, 24/28 (85.7%) surgical and 77/
90 (85.6%) catheter patients had discontinued Class I/III antiarrhyth-
mic drugs (P= 0.99). Arrhythmia-free survival at specific time points
is shown in Table 4. A graphical representation of cardiac rhythm
post-VATS ablation is shown in Figure 3.
Discussion
Video-assisted thoracoscopic surgery AF ablation is increasing in
popularity. However, the published data on VATS AF are highly vari-
able, and the overall 2.8% major complication rate reported by a re-
cent meta-analysis3 suggested possible publication bias. In particular,
few series have involved independent review of outcomes by cardiol-
ogists. In this article, involving joint analysis of all outcomes by both
cardiologists and surgeons, we show that while the success rates
with VATS AF ablation are encouraging, the procedure carries a sig-
nificant risk of major complications during a centre’s initial experi-
ence. Furthermore, a contemporaneous propensity-matched cohort
of patients undergoing CA suggested that rates of freedom from ar-
rhythmia may be similar but that CA carries a significantly lower pro-
cedural risk.
While one recent randomized trial showed similar efficacy be-
tween VATS and CA,13 four small randomized trials7,14–16 and three
cohort studies17–19 (Table 5) have previously suggested that VATS
ablation is associated with greater success than CA. Accordingly, the
European Society of Cardiology guidelines on AF (2016)2 gave a
Class IIa indication for standalone VATS AF ablation for non-
paroxysmal AF. In contrast with the earlier comparative studies, why
has no difference in success rates been found between catheter and
VATS ablation by ourselves or by the most recent trialists?
Figure 2 Outcomes. Kaplan–Meier curves of survival free from atrial arrhythmias after 3-month blanking period. (A) Single procedure and
(B) Allowing for a single additional catheter ablation.
.................................................................................................
Table 4 Arrhythmia-free survival
6 months 12 months Last
follow-up
Surgical
Off AADs 16/28 (57.1%) 15/27 (55.6%) 13/29 (44.8%)
±AADs 20/28 (71.4%) 16/27 (59.3%) 15/29 (51.7%)
±RFCA and AADs 24/28 (85.7%) 21/27 (77.8%) 18/29 (62.1%)
Catheter
Off AADs 54/84 (64.3%) 37/65 (56.9%) 50/90 (55.6%)
±AADs 61/84 (72.6%) 44/65 (67.7%) 53/90 (58.9%)
±RFCA and AADs 69/84 (82.1%) 52/65 (80.0%) 62/90 (68.9%)
AADs, Class I/IV antiarrhythmic drugs; RFCA, allowing for a single additional
catheter ablation.
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Firstly, it is highly likely that CA has become more effective since
the earlier comparative trials shown in Table 5 were reported. Most
studies comparing VATS with CA recruited patients from 2006 to
2011, a period during which CA technology was rapidly evolving, and
before contact force-sensing catheters were available. The 12-month
success rates from CA in these studies are as low as 30% for paroxys-
mal16 and 32% for persistent AF,19 considerably lower than the
65%20 reported in a recent meta-analyses of CA for persistent AF.
However, the pooled estimates from meta-analyses of CA are similar
to the results from CA presented here, suggesting that as CA tech-
nology has improved, the previously seen advantages of VATS AF ab-
lation may no longer be as apparent. These rates of freedom from
recurrent arrhythmia seen following CA are similar to those follow-
ing VATS ablation despite less linear ablation, consistent with studies
showing no advantage to lesion sets beyond PVI.21
It is possible VATS ablation performed during a centre’s early ex-
perience might be less effective than procedures performed after
more experience has been accrued. As shown in Table 5, 12-month
success rates ranged from 66% to 90%, similar to a recent meta-
analysis reporting a pooled 12-month success of 72%.3 However,
many of these studies recruited a high proportion of patients with
paroxysmal AF in whom ablation might be expected to be more suc-
cessful. Furthermore, definitions of success varied across studies with
some using only a point prevalence of sinus rhythm as their primary
outcome, a definition which might inflate apparent success. In con-
trast, we used a guideline-derived definition of success in a cohort of
patients with advanced disease. In view of this, our 12-month success
rate of 59% in a cohort predominantly comprising non-paroxysmal
AF is broadly comparable with the existing literature, suggesting that
the impact of the learning curve on success rate has been small.
When comparing rates of PV reconnection, the small proportion of
patients who underwent repeat CA make comparisons with existing
literature difficult. Bearing this in mind, the mean of 1.0 reconnected
veins reported here is numerically but not statistically higher than the
mean 0.4 veins per patient reported following simultaneous hybrid
surgical and CA.22
Whilst the relative success rates of VATS and CA reported here
differ from those reported elsewhere, our finding that thoracoscopic
AF ablation is associated with a higher rate of major complications is
consistent with previous work. Our complication rate from VATS
ablation of 20% is similar to the 21–35% rate seen in trials in which
outcomes have been reported jointly by cardiologists and surgeons
(Table 5), although markedly higher than the 2.9% described in a re-
cent meta-analysis of the surgical literature.4 This meta-analysis ac-
knowledged that under-reporting was likely to be present in many of
the included case series which did not include a comparator arm.
The incidence of complications is highly variable within the surgical
literature, for example the rate of conversion to sternotomy
...................................................... ................................................
....................................................................................................................................................................................................................
Table 5 Comparison with other studies of catheter vs. surgical ablation
Study n Percentage
of PAF
Recruitment 12-month success off AADs (%) Major complication rate (%)
CA SA CA SA
Boersma et al.7 RCT 124 59% 2007–10 36 66 3 23
Pokushalov et al.15 RCT 64 56% 2011 47 81 2 21
Wang et al.14 RCT 138 100% 2008–12 75a 89a – –
Sugihara et al.16 RCT 70 100% 2012–15 30 90 0 35
Adiyaman et al.13 RCT 52 74% Uncertain 56 33 0 22
Wang et al.17 Cohort 166 0% 2006–09 59 75 0b 1b
De Maat et al.18 Cohort 99 73% 2009–11 42 87 5 21
Haldar et al.19 Cohort 51 0% 2011–13 32 73 8 27
This study Cohort 120 8% 2013–16 66 50 1 20
AADs, Class I/IV antiarrhythmic drugs; CA, catheter ablation; PAF, paroxysmal atrial fibrillation; RCT, randomized controlled trial; SA, surgical ablation.
aPoint prevalence of sinus rhythm.
bPartial complication reporting only.
Figure 3 Cardiac rhythm following surgical ablation. DCCV, di-
rect current cardioversion.
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following bleeding varies from 0% to 10%.7,13,16,23–25 Comparing
composite complication rates is made even more challenging by vari-
able definitions of major and minor complications. While we have
used the Ottawa Thoracic Morbidity and Mortality classification sys-
tem according to which complications requiring operative re-
intervention e.g. pacemaker implant or pericardiocentesis are classed
as major complications, other large series have described complica-
tions such as these as minor,26 or avoided distinguishing between
severities of complication,25 confounding a direct comparison of
headline figures. Higher rates of major complications have been asso-
ciated with VATS ablation involving ganglionic plexus ablation,27 but
the majority of cases described in this series had already taken place
before the AFACT study describing this association had been
published.
Our complication rate from CA is slightly lower than reported in
other comparative trials, potentially due to our routine use of
ultrasound-guided vascular access minimizing the risk of vascular
complications.10
Limitations
While the surgeon who performed the thoracoscopic ablation was
highly experienced in thoracoscopic surgery, this series of cases fell
within his learning curve for VATS AF ablation. To compare surgical
results with an established high-volume CA service could be consid-
ered unfair. However, 20 of the first 30 VATS cases were proctored
by experienced surgeons from other centres. Furthermore, our ex-
perience reflects the reality of any new surgical AF service establish-
ing itself in an era when CA AF ablation has become commonplace.
The usage of ambulatory monitoring was lower in the CA cohort,
potentially missing AF recurrences and overestimating CA success.
However, the incremental benefit of ambulatory monitoring over 12-
lead ECGs lies in the detection of asymptomatic paroxysmal AF. The
overwhelming majority of patients in both cohorts had symptomatic
persistent or longstanding-persistent AF. Given the sustained nature
of the arrhythmias experienced by these patients, it is unsurprising
that no patient in either cohort had a recurrence of AF detected
solely on ambulatory monitoring which was not also documented on
12-lead ECG. Any overestimation of success in the CA cohort caused
by a lower use of ambulatory monitoring is therefore likely to be
small.
In addition to preventing recurring arrhythmia, the VATS cohort
also underwent LAA exclusion with the aim of reducing long-term
stroke risk. The outcomes reported here do not take into account
this potentially important benefit. Performing routine LAA exclusion
and performing a more extensive lesion set in the CA cohort may
have led to higher complication rates. It is possible the lesions created
by VATS ablation are more durable, and that isolation of the left trial
appendage may have reduced long-term risk of stroke, and extended
follow-up may therefore have revealed a difference between groups.
The data on the VATS cohort were collected and assessed pro-
spectively, whereas the data from the matched CA cohort were col-
lected prospectively but collated retrospectively (once propensity
matching had identified relevant patients). While major complications
are likely to have been identified, it is possible that minor complica-
tions in the CA group may have been missed. However, it remains
unlikely that a potential under-reporting of minor complications in
the CA cohort would influence the overall message that the major
complication rate for VATS ablation is significantly higher than those
reported by selected high-volume centres. Finally, although every at-
tempt has been made to provide a representative comparator group
for the VATS ablation group, the accuracy of propensity matching is
reduced when dealing with small cohorts. The demographics of the
two cohorts appear well matched, but possible residual differences in
unmeasured characteristics cannot be excluded.
Conclusions
Comparing two groups of patients with advanced AF, we suggest
that during a centre’s initial experience VATS ablation may be associ-
ated with similar success rates to CA, but that VATS ablation may
carry a considerably higher complication rate. Cardiothoracic units
considering establishing a VATS ablation programme should be
aware that initial results may not match the results reported by some
established high-volume centres, and that CA may potentially offer
equivalent success rates at a lower risk of complications. These find-
ings highlight the need for verification of long-term outcomes using
randomized trials comparing VATS ablation with current CA
technology.
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